Project Grant R01CA296261
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $646K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a Project Grant of $671,252 under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026, through June 30, 2031. This five-year research initiative investigates the mechanisms by which CD4 T cells and dendritic cells (DC) work in concert with CD8 T cells to enhance anti-tumor immunity. Specifically, the research focuses on understanding how...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $1,098,920 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on August 13, 2025, with a completion date of April 30, 2030. The grant supports fundamental research to understand the transcriptional and epigenetic mechanisms controlling CD8+ tumor-infiltrating lymphocytes (TILs), with specific focus on the transcription...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Scripps Research Institute a Project Grant totaling $748,410 on June 19, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop targeted degradation therapies for glycoimmune checkpoints. The research focuses on creating heterobifunctional degrader molecules that simultaneously target Siglec-7 and Siglec-9 proteins to the lysosome for degradation. These checkpoint proteins are expressed by myeloid cells...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $648,626 to the University of California Irvine on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support a five-year project extending through March 31, 2031. This Project Grant funds fundamental research investigating the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI), specifically examining how PD-1 (Programmed Death-1) inhibition affects tumor...
- Federal Grant Award Summary The Beckman Research Institute of the City of Hope received a $694,015 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), awarded July 1, 2026, with a completion date of June 30, 2031. The research project, titled "Identifying and Targeting Cancer Immune Evasion Signals Against Macrophage Surveillance," focuses on identifying and characterizing phagocytosis checkpoints that regulate macrophage-mediated...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a $630,089 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective May 1, 2026, through April 30, 2031. This award funds research to characterize the molecular functions of SMARCAL1, a DNA translocase protein involved in regulating anti-tumor immune responses. The research addresses a critical gap in cancer immunotherapy by...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Grant Award Summary The National Cancer Institute awarded a $663,998 Project Grant to the University of California, San Diego effective July 13, 2026, through the Cancer Treatment Research program (CFDA 93.395) to support research on mechanistic targeting of the Type I Interferon (IFN) pathway to improve cancer therapy efficacy. The research focuses on ubiquitin specific protease 18 (USP18), identified as a major negative regulator of IFN signaling that limits the therapeutic...